Australia’s largest trial of ketamine to treat depression begins

The largest randomised control trial to evaluate the effectiveness of ketamine as a new treatment for major depression has begun across Australia and New Zealand.

The three-year trial will enrol 200 adult patients who have not responded to existing medications for major depression. Researchers will compare the effects of twice-weekly ketamine treatment against an active placebo treatment over a four-week period.

Major depression is diagnosed when a person experiences a low mood for two weeks or more and this has a significant impact on daily functioning.

The first NSW-based patients begin treatment this week, with Victoria expected to recruit its first patients in the next few months. Five other sites in Australia and New Zealand will also take part in the trial.

Ketamine research leader UNSW Professor Colleen Loo, who is based at the Black Dog Institute, said the study would build on five years of UNSW experience in ketamine research.

“Ten separate randomised, placebo-controlled trials involving about 250 participants worldwide have shown a single dose of ketamine produces rapid antidepressant effects within hours, even in treatment-resistant patients. However, attaining lasting remission remains a challenge,” Professor Loo said.

“This trial will allow us to examine the effects of repeated dosing and whether the positive effects of ketamine on an individual’s depression can be sustained over a longer period.”

The randomised double blind trial, the gold standard for clinical research, means neither the researchers nor patients know whether they will be receiving ketamine or a placebo.

After the initial treatment period, patients will be monitored over a four-week period to assess the impact of ketamine on patients’ mood. Patients enrolled in the trial may then also have an opportunity to receive the ketamine treatment after the initial phase of the trial is completed. Professor Loo said an evidence-based approach to assessing the effectiveness and safety of ketamine as a depression treatment was crucial.

“Some clinics in Australia and overseas continue to offer off-label ketamine treatments to patients with depression in an unsafe manner and with minimal care,” Professor Loo said.

“This practice is premature and irresponsible, given that the effectiveness and safety of this treatment approach involving repeated dosing has yet to be tested in controlled trials.

“We will be working very closely with clinical pharmacologists during this trial to understand the specific dosage required for each individual and the likely effects it will have,” Professor Loo said.

The ketamine will be administered to patients via a needle into subcutaneous tissue, much like an insulin injection. The trial is being funded by a $2.1 million grant from the National Health and Medical Research Council.

The trial is taking place at the following sites across Australia and New Zealand:

• UNSW/Black Dog Institute, Sydney
• University of Otago, Dunedin
• Sir Charles Gairdner Hospital, Perth
• South Eastern Private Hospital, Victoria
• Brain and Mind Centre/ Royal Prince Alfred Hospital, Sydney
• Adelaide University/Royal Adelaide Hospital, Adelaide
• Monash Alfred Psychiatry Research Centre, Melbourne

NSW-based patients who are interested in enrolling in the trial should email: ket.study@unsw.edu.au. Other sites will advertise for patients in the coming months.

For more information about the trial visit the Black Dog website.

(Source: UNSW)